The salivary metatranscriptome as an accurate diagnostic indicator of oral cancer

Abstract

Despite advances in cancer treatment, the five-year mortality rate for oral cancers (OC) is 40%, mainly due to the lack of early diagnostics. To advance early diagnostics for high-risk and average-risk populations, we developed and evaluated machine-learning (ML) classifiers using metatranscriptomic data from saliva samples (n=433) collected from oral premalignant disorders (OPMD), OC patients (n=71) and normal controls (n=171). Our diagnostic classifiers yielded a receiver operating characteristics (ROC) area under the curve (AUC) up to 0.9, sensitivity up to 83% (92.3% for stage 1 cancer) and specificity up to 97.9%. Our metatranscriptomic signature incorporates both taxonomic and functional microbiome features, and reveals a number of previously known and novel taxa and functional pathways associated with OC. For the first time, we demonstrate the potential clinical utility of an AI/ML model for diagnosing OC early, opening a new era of non-invasive diagnostics, enabling early intervention and improved patient outcomes.

A winning combination in the war against deadly cancers: exploring new opportunities for combining antibody–drug conjugates and cancer immunotherapies

“…Furthermore, artificial intelligence was used to predict microsatellite instability and deficient DNA mismatch repair in hematoxylin and eosin stained colorectal cancer sections with high accuracy in uniform datasets [55]. Artificial intelligence and machine learning have also been used in developing biomarkers for early detection of head and neck cancer by assessing metatranscriptomic data from saliva samples from normal, potentially malignant and malignant oral tissues [56].…”

Microbiota changes: the unseen players in cervical cancer progression

“…From this wealth of research, a startling revelation has emerged: approximately 20% of all fatal cancers are microbially induced (Godoy-Vitorino et al, 2018). Moreover, numerous studies have drawn significant correlations between alterations in the microbiome and cancer phenotypes (Elinav et al, 2019;Poore et al, 2020;Banavar et al, 2021). This underlines the potential of the microbiota as a treasure trove of biomarkers that could revolutionize clinical diagnostics and disease management.…”